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Abstrad
Transitions between the small cell lung cancer and the
non-small cell lung cancer phenotype occur during
clinical tumor progression in small cell lung cancer. We
have previously developed a culture model which
mimics these transitions. In our model, the insertion of
the v-Ha-ras oncogene into c-myc overexpressing
NCI-H82 small cell lung cancer cells induces features
charaderistic of non-small cell lung cancer. We now
report that treatment of NCI-H82 cells with 1 ￿M
all-trans-retinoic acid resulted in decreased cellular
growth, decreased c-myc mRNA levels, and increased
l-myc mRNA levels. Retinoic acid treatment prior to
v-Ha-ras insertion also inhibited the typical ras-induced
phenotypic transition seen in untreated NCI-H82 cells.
In contrast, retinoic acid treatment of NCI-H82 ras cells
after ras-induced transition to the non-small cell lung
cancer phenotype did not affed cellular phenotype, nor
c-myc or l-myc gene expression. These data show that
all-trans-retinoic acid, a clinically relevant compound,
inhibits small cell lung cancer progression in our in vitro
model and alters the expression of the c-myc and L-myc
oncogenes. These findings suggest mechanisms for the
biological effects of retinoic acid in small cell lung
cancer.
Introdudion
Lung cancer continues to be a major health care concern in
the United States, with 168,000 new cases and 146,000
deaths estimated in 1992 (1). SCLC3 is a distindt chinico-
pathological entity which comprises 25% ofall cases of lung
cancer and is characterized by early metastatic potential and
good initial response to therapy. Unfortunately, despite mi-
tial responsiveness, nearly all patients with SCLC eventually
relapse and die with treatment-resistant disease (2). The bio-
logical mechanisms underlying tumor progression in SCLC
are poorly understood. However, clinical studies have dem-
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onstrated a 25-40% incidence of conversion from SCLC to
NSCLC during treatment (3, 4). These data suggest that one
component of tumor progression may be movement of the
SCLC phenotype along a differentiation continuum linking
SCLC with NSCLC (5).
In order to study the events involved in SCLC progression,
we previously developed an in vitro model which mimics
the phenotypic transitions seen in clinical practice. In this
model, insertion and expression of an activated v-Ha-ras
oncogene into NCI-H82 or NCI-H249 SCLC cells, which
overexpress the c-myc and N-myc oncogenes, respectively,
induce the acquisition offeatures typical ofthe NSCLC phe-
notype (6, 7). These features include: adherent monolayer
growth, decreased doubling time, increased cloning effi-
ciency, resistance to polyamine depletion with DFMO, loss
ofneuroendocrine markerexpression, and expression of epi-
thelial cell markers. The role of c-myc gene dysregulation in
this ras-induced phenotypic transition was examined by
studying NCI-H209 classic SCLC cells which overexpress
only the L-myc oncogene. These NCI-H209 cells maintain
their SCLC characteristics despite the insertion and overex-
pression of the v-Ha-ras ondogene. When an exogenous
c-myc gene is overexpressed in NCI-H209 cells (NCI-H209
myc), they acquire some features of the variant SCLC phe-
notype (8). Insertion of v-Ha-ras into NCI-H209 myc cells
results in the acquisition of NSCLC features similar to those
seen in the NCI-H82 model system. This model suggests that
c-myc gene dysregulation in conjunction with other genetic
derangements, such as ras mutation, may mediate the de-
velopment of a treatment-resistant phenotype. We now
show that RA, an agent which profoundly influences the
differentiation of normal bronchial epithelial cells (9), can
block the ras-myc complementation events which induce
the in vitro transition from the SCLC to the NSCLC pheno-
type. We also show that alterations in myc family gene ex-
pression are associated with the effects of RA on lung cancer
phenotype.
Results
Effects of All-trans-Retinoic Acid on Variant SCIC Cell line
NCI-H82. We first examined the effedts of continuous ex-
posure to 1 ￿M RA on NCI-H82 SCLC cells. NCI-H82 is clas-
sified as a variant cell line due to low levels of neuroendo-
crine markers, rapid doubling time, and c-myc gene
amplification and overexpression. Doyle et a!. (10) previ-
ously reported that RA treatment induced a more classic
SCLC phenotype in these cells, an observation which we
have confirmed. Morphologically, untreated NCI-H82 cells
grew in culture as loose, irregular suspended clusters. In
contrast, NCI-H82 cells exposed to 1 ￿M RA (NCI-H82 RA)
grew in tighter, more spherical clusters, a growth pattern
characteristic of classic SCLC cell lines (Fig. 1). NCI-H82
RA cells also grew more slowly than untreated NCI-H82
cells (Fig. 2).‘I
￿:￿:￿‘ ￿ ‘ ,￿ ‘ c￿tM;s ￿
‘I, ￿ ￿ ￿ , ,1:.f￿, Gb ￿ .
￿ ￿ ￿
￿; ￿
p
#￿
“fi
￿
￿ p /‘￿_
r￿-w--
￿ ￿
, C
(I
i-±-
Fig. 1. Photoniicrographs of: A NCI.H82 cells; (B) NCI-H82 RA cells treated with 1 ￿M RA; (C) NCI-H82 ras cells after v-Ha-ras infection; (D) NCI-H82 RA+ ras
( (‘II’, treate(l with RA before v-Ha-ras infection; and (E( NCI-H82 ras+RA cells treated with RA after ras-induced phenotypic transition.
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Effects of All-trans-Retinoic Acid on myc Family Gene
Expression. Our previous work showed that overexpression
of c-rnyc, but not of L-rnyc, was capable of complementing
v-Ha-ras in our SCLC tumor progression model (6, 1 1).
c-rnyc gene amplification and overexpression are stable
characteristics of NCI-H82 SCLC cells. We examined c-myc
gene expression in NCI-H82 cells before and after RA treat-
ment and found that within 1 2 h of treatment with 1 psi RA,
c-rnyc: mRNA expression in NCI-H82 cells was markedly
diminished (Fig. 3).
We also investigated the effects of RA on two other irn-
portant members ofthe rnycgene family, L-mycand N-myc.
Since RA exposure appears to induce a more classic SCLC
phenotype and L-rnyc overexpression is associated with
classic SCLC cells in culture, we predicted that L-myc gene
expression may be altered in NCI-H82 cells treated with RA.
Indeed, NCI-H82 cells exposed to 1 ￿M RA exhibited a
marked increase in steady-state L-myc mRNA levels (Fig. 3).
This up-regulation of L-rnyc gene expression was noted by
12 h after initiation of RA treatment. In contrast, no sign ifi-
cant changes were noted in steady-state N-myc mRNA levels
in NCI-H82 cells after exposure to 1 ￿M RA (data not shown).
Thus, we found that, in NCI-H82 cells, treatment with RA
resulted in a down-regulation of c-myc transcripts and an
up-regulation of L-myc transcripts.
All-trans-Retinoic Acid Inhibits Phenotypic Transition
from SCLC to NSCLC. Since NCI-H82 cells treated with RA
exhibited a marked decrease in c-rnyc gene expression, we
predicted that RA may abrogate the ras-induced phenotypic
transition which we had previously characterized in our
model. This transition has been defined by the biological
differences between SCLC and NSCLC cells in culture. SCLC
cells grow as suspended cellular aggregates, express high
levels of neuroendocrine markers, and are sensitive to ra-
diation exposure and polyamine depletion with DFMO (1 2).
In contrast, NSCLC cells grow in attached monolayers, ex-
press high levels of epithelial markers, and are relatively
resistant to both radiation and DFMO (1 2). NCI-H82 SCLC
cells were exposed to 1 ￿M RA continuously for 5-7 days
prior to v-Ha-ras insertion (NCI-H82 RA+ras) to maximally
down-regulate c-myc rnRNA levels. Treatment with RA did
not interfere with the ability of these cells to express the
inserted v-Ha-ras gene. This was documented by the dem-
onstration of equally high levels of v-Ha-ras mRNA in Ha-
MSV infected NCI-H82 cells with or without prior RA treat-
ment (Fig. 4). These RNA samples were derived from the
same cell populations that were used for the growth and myc
gene expression studies reported in this paper. NCI-H82
RA+ras cells failed to undergo the phenotypic transition
which is typical of NCI-H82 ras cells without prior RA treat-
ment. Instead, NCI-H82 RA+ras cells maintained the phe-
notypic characteristics of cultured SCLC cells. NCI-H82
RA+ rascells grew in irregular suspended cellular aggregates
which resembled NCI-H82 cells (Fig. 1), and their doubling
time was intermediate between that of NCI-H82 and NCI-
H82 RAcelhs(Fig. 2). NCI-H82 RA+rascehls also were sen-
sitive to DFMO, a trait which is typical of SCLC (Fig. 5). In
contrast, as in our previous studies, v-Ha-ras infection of
non-RA-treated NCI-H82 cells (NCI-H82 ras) induced
NSCLC characteristics, including anchorage-dependent
growth (Fig. 1), shorter doubling time (Fig. 2), and resistance
to DFMO (Fig. 5).
All-trans-Retinoic Acid Has No Effect on NCI-H82 ras
Phenotype. Since we had demonstrated that the ras-
induced phenotypic transition of NCI-H82 cells was inhib-
ited by RA, we next determined whether the acquisition of
NSCLC features after v-Ha-ras insertion could be reversed by
RA. NCI-H82 ras cells with typical NSCLC phenotype were
exposed to 1 ￿M RA (NCI-H82 ras+ RA). Despite RA treat-
ment, these NCI-H82 ras+RA cells exhibited no changes in
their NSCLC characteristics. They continued to grow as ad-
herent monohayers (Fig. 1) with short doubling time (Fig. 2)
and DFMO resistance (Fig. 5). Also, unlike NCI-H82 RA and
NCI-H82 RA+ ras cells, NCI-H82 ras+ RA cells continued toNCI-H82 RA
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Fig. 3. Northern hybridization with 10 pg of P0IY(A( ‘ RNA/lane from NCI-
H82 RA cells harvested at 0, 12, and 24 h after initiation of continuous treat-
ment with 1 ￿M RA. Blot was probed with exon 3-specific c-mvc and L-mvc
probes and a human f3-actin probe.
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Fig. 2. Growth curves for NCI-H82 cells with and without v-Ha-ras infection
and/or treatment with 1 p￿a RA. Values presented are the mean of triplicate
samples in three experiments. Bars, SE. Note increased doubling time of Nd-
H82 RAand RA+rascells, anddecreaseddoublingtimeofNCt-H82 rasand
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mRNA (Fig. 6). Therefore, NCI-H82 ras cells which have
already undergone ras-induced transition to the NSCLC phe-
notype appear to be refractory to the effects of RA on myc
family gene expression and cellular phenotype.
Discussion
The phenotypic plasticity of hung cancer has been demon-
strated in numerous clinical and laboratory studies (3-5).
Although transitions from the SCLC to the NSCLC phenotype
Fig. 4. Northern hybridization with 20 pg of total RNA/lane from the noted
cell lines probed with the coding region of the v-Ha-ras gene. This RNA was
have been implicated in the clinical progression ofSCLC, the
genetic events involved are poorly understood. Our labo-
. . .
ratory has previously demonstrated that genetic manipula-
tion of SCLC cells in vitro could induce transition to the
derived from cell populations which were then used in the growth and tiWC
geneexpressionstudiesinthispaper. Lanes3and4(NCI-H82 RA+ras),RNA
from two different v-Ha-ras infection experiments. Note comparable over-
expression of v-Ha-ras with or without RA treatment. Equivalent loading was
demonstrated by ethidium bromide staining (not shown.
NSCLC phenotype (5). In our model, v-Ha-ras insertion into
NCI-H82 SCLC cells, which overexpress c-myc, results in
the acquisition of numerous features of NSCLC (6). The pre-
sent study shows that RA can inhibit this ras-induced phe- sponse to RA when treated after the ras-induced transition to
notypic transition, while also affecting myc family gene ex- the NSCLC phenotype had occurred.
pression. When exposed to RA, NCI-H82 cells exhibited ThestirnulatoryeffectofRAon L-rnycgeneexpression has
increased doubling time, decreased c-myc mRNA levels, previously been reported only in embryonal carcinoma cells
and increased L-myc mRNA levels. When these RA-treated (1 3). In contrast, the suppression of c-myc and N-myc gene
NCI-H82 cells were infected with a retrovirus containing the expression has been associated with retinoid-induced dif-
v-Ha-ras oncogene, they failed to undergo the phenotypic ferentiation in a nurnberofcelh systems (14-i 7). The mecha-
transition typical of untreated NCI-H82 cells. In contrast, nisms involved in the regulation of myc gene expression in
NCI-H82 ras cells exhibited no discernible biological re- our system have not yet been determined, so it is not possible
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Fig. 5. Growth curves in the presence of DFMO for NCI-H82 cells with and
without v-Ha-ras infection and/or treatment with 1 psi RA. Note that DFMO
is cytotoxic for cells with SCLC phenotype (NCI-H82; NCI-H82 RA+ras(, but
not for cells with NSCLC phenotype (NCI-H82 ras; NCI-H82 ras+RA(.
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at this time for us to state whether myc gene regulation is a
direct or indirect result of RA exposure. The reciprocal
changes observed in c-myc and L-myc gene expression sug-
gestthat cross-regulation ofthe mycgenes may be involved.
Although cross-regulation of c-myc and N-myc gene expres-
sion has been well described (18), it has not been deter-
mined whether this phenomenon occurs between L-myc
and the other myc genes. Studies in our laboratory with NCI-
H82 cells engineered to overexpress an exogenous RAR-y
gene (NCI-H82 RAR-y) suggest that the c-myc and L-myc
genes may be independently regulated. In these studies, RA
treatment of NCI-H82 RAR-y cells resulted in increased
L-myc expression but failed to suppress c-myc expression.4
These findings argue against cross-regulation of c-myc and
L-myc expression in our system. Further studies to determine
the mechanisms involved in RA-induced myc gene regula-
tion in NCI-H82 cells are currently under way.
Little is known about the normal physiological actions of
L-myc or its potential role in the pathophysiology of lung
cancer. In our earlier work, we showed that SCLC cells
which overexpress the L-myc oncogene are not competent
to undergo ras-induced transition to the NSCLC phenotype
(5). However, if an exogenous c-myc gene is overexpressed
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Fig. 6. Northern hybridization with 10 pg of poly(A)’ RNMane from the
noted cell lines probed with exon 3-specific c-myc and L-myc probes and a
human /3-actin probe. All cells were harvested during log phase growth. RA-
treated cells were harvested after 5-7 days ofexposure to 1 ￿M RA ( Lanes 3-5).
in these cells prior to v-Ha-ras insertion, they will develop
features of NSCLC, despite continued L-mycexpression (1 1).
These data demonstrated that c-myc gene overexpression is
a necessary prerequisite for this ras-induced transition from
the SCLC to the NSCLC phenotype. Therefore, the down-
regulation of c-myc expression induced by RA in NCI-H82
cells may be a critical mechanism by which RA inhibits pro-
gression in our model system. Recent reports that reduced
G-protein levels are associated with RA-induced differen-
tiation in F9 cells, and that a reduction of G-protein levels
can mimic this differentiation in the absence of RA, suggest
that RA also may interfere with ras-mediated pathways in our
system (19).
The inability of RA to reverse the ras-induced NSCLC phe-
notype in NCI-H82 ras+RA cells is accompanied by a per-
sistence of c-myc gene overexpression . Th is fi nd ing suggests
that v-Ha-ras overexpression in NCI-H82 ras cells makes
them refractory to RA-initiated signals. The mechanisms in-
vohved in this are not yet known, but perhaps the overex-
pression of an activated ras product irreversibly inactivates
or bypasses one or more components of the retinoid-
mediated signaling pathways within these cells.
An extensive body of prechinicah work has shown that reti-
noids play an important role in cellular differentiation within
the normal lung and suggests that the use of RA in lung
cancer therapy deserves careful consideration. Vitamin A
deficiency causes reversible squamous metaplasia, a pre-
malignant lesion, of the respiratory epithehiurn in animals
and organ culture models (20, 21 ). Recently, it has been
found that abnormalities of RAR-j3 gene expression and in-
duction are common in lung cancer (22). The effects of reti-
noids on SCLC cells in culture have only recently begun toCell Growth & Differentiation 59
be examined. In one study, a SCLC cell line deprived of
vitamin A developed features of squamoid differentiation
which reverted upon addition of RA to the culture media
(23). Also, Doyle and coworkers treated the SCLC cell line
NCI-H82 with RA and reported decreased growth, de-
creased c-myc gene expression, and increased sensitivity to
etoposide (10). These prechinical findings predict that per-
turbations of retinoid signaling pathways may contribute to
the dysregulation of differentiation and growth associated
with malignant transformation and tumor progression. Our
findings lend further support to the association between reti-
noids and lung cancer differentiation.
Pharmacological modulation of oncogenes and their
products represents a novel approach to the treatment of
cancer. Reti noid-i nduced d ifferentiation has been associ-
ated with a decrease in c-mycgene overexpression in HL6O
promyelocytic leukemia (1 4) and F9 teratocarcinoma cells
(1 5), and with a decrease in N-myc overexpression in neu-
roblastorna cells (1 7). In SCLC, increased expression of
c-myc, with or without gene amplification, occurs corn-
monly along the tumor progression pathway and is associ-
ated with poor prognosis (24). In this report, we have shown
that RA down-regulates c-myc gene expression and inhibits
the induction of phenotypic features associated with tumor
progression. These data suggest that modulation of c-myc
oncogene expression by RA in SCLC may head to a poten-
tially useful new therapeutic approach in some patients with
this disease.
Materials and Methods
Cell Culture. The well-characterized human SCLC cell line
NCI-H82 was cultured at 37#{176}C in RPMI 1640 medium
(Sigma) supplemented with 2% (v!v) fetal bovine serum
(Sigma), 100 units of penicilhin!mI, 100 ￿ig streptomycin
sulfate,’ml, and HITES [hydrocortisone (1 08 M), insulin (15
pg/mI), transferrin (1 00 ￿ig/rnl), 17￿-estradioI (1 0_8 si), and
selenium (3 X 10-8 M)] (25). RA-treated NCI-H82 cells were
continuously exposed to 1 ￿M RA (Sigma).
Retroviral Infedion. Insertion of v-Ha-ras was performed
as previously described (26). Briefly, NIH-3T3 cells infected
with Ha-MSV and 1504A amphotropic murine leukemia
helper virus (27) were grown in DMEM (GIBCO) supple-
rnented with 9% (v,’v) fetal bovine serum. For retroviral in-
fection, 10 pg Pohybrene (Sigma)!ml were added to NCI-H82
cells in fresh RPMI 1640 culture medium, followed by the
addition of an equal volume of conditioned medium from
the infected NIH-3T3 cells which produce high titers of Ha-
MSV.
Growth Studies. Cells were seeded in 6-well plates at a
densityof2 x 10￿ cehls,’well. Cell numbers were determined
every 2 days by hemocytometer counts. Prior to counting,
cells were briefly trypsinized, washed, and triturated to
closely approximate a single cell suspension. Multiple
counts were done on triplicate samples for each time point,
and both the average and SE were calculated from these
counts. To evaluate the effect of polyamine depletion, 5 mxi
difluoromethylornithine was added to cells at the time of
plating, and cell numbers were serially determined as noted
above.
Northern Blot Analysis. Total RNA was isolated using the
acid-phenol-guanidinium isothiocyanate method (28).
Poly(A)￿ RNA was isolated by oligo(dT)-cellulose chroma-
tography (29). Either 20 pg oftotal RNA or 10 pg of poly(AY5
RNA were fractionated on 1 .5% agarose-2.2 M formalde-
hyde gels and transferred to nylon membranes. Hybridiza-
tions were performed with the following complementary
DNA inserts labeled with [a-32PJdCTP by nick translation:
v-Ha-ras, 730-base pair Ssll-PstI fragment (Oncor, Gaithers-
burg, MD); human ￿3-actin, 2.2-kb BamHl fragment (kindly
provided by Don Cleveland, Johns Hopkins University);
c-myc exon 3, 1.4-kb C!al-EcoRl fragment; L-myc, 1 .8-kb
Smal-EcoRl fragment (kindly provided by John Minna, Na-
tional Cancer Institute). After hybridization, membranes
were washed at 65#{176}C in 2 X standard saline citrate-i % so-
dium dodecyl sulfate for 30 mm and then autoradiographed
at -70#{176}C with intensifying screens.
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